<DOC>
	<DOCNO>NCT02833792</DOCNO>
	<brief_summary>STUDY OBJECTIVES Primary : To assess safety tolerability ischemia-tolerant allogeneic human mesenchymal stem cell ( hMSCs ) manufacture Stemedica versus placebo administer intravenously subject mild moderate dementia due Alzheimer 's disease . Secondary : To assess preliminary efficacy hMSCs versus placebo subject Alzheimer's-related dementia , evidence neurologic , functional , psychiatric endpoint .</brief_summary>
	<brief_title>Allogeneic Human Mesenchymal Stem Cells Alzheimer 's Disease</brief_title>
	<detailed_description>This Phase IIa multi-center , randomize , single-blind , placebo-controlled , crossover study subject mild moderate dementia due Alzheimer 's disease . Only subject caregiver blind study treatment . The study consist two cohort subject ( 20 subject per cohort ) , randomize 1:1 allocation receive active study drug placebo . Cohort 1 receive single intravenous dose hMSCs 1.5 million cell per kilogram body weight Study Day 1 , Cohort 2 receive equal volume Lactated Ringer 's Solution Study Day 1 . At six-month time point subject first infusion , Cohort 1 receive single intravenous dose Lactated Ringer 's Solution Cohort 2 receive single intravenous dose hMSCs 1.5 million cell per kilogram subject 's body weight . Approximately 40 subject enrol study . An independent Data Safety Monitoring Board conduct periodic safety review .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>1 . Males females 5580 year age . 2 . Diagnosed mild moderate dementia least 3 month prior enrollment , base National Institute Neurological Communicative 3 . Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINDSADRDA ) Alzheimer 's criterion . 4 . MMSE 1224 ( inclusive ) time enrollment . 5 . Amyloidpositive florbetapir PET scan . 1 . Prior treatment stem cell . 2 . History intracranial , subdural , subarachnoid hemorrhage . 3 . Subjects baseline brain MRI show four ( 4 ) cerebral microhemorrhages ( regardless anatomical location diagnostic characterization `` possible '' `` definite '' ) , and/or one ( 1 ) area superficial siderosis , and/or evidence prior macrohemorrhage . MRI must include fluidattenuation inversion recovery ( FLAIR ) T2*weighted gradientrecalledecho ( GRE ) sequence . 4 . History cancer within past 5 year , exception localize basal squamous cell carcinoma . 5 . History seizure disorder . 6 . Diagnosis cerebral autosomal dominant arteriopathy subcortical infarct leukoencephalopathy ( CADASIL ) . 7 . History cerebral neoplasm . 8 . Myocardial infarction within six month enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>